Capricor Therapeutics Files Definitive Proxy Statement

TL;DR

<b>Capricor Therapeutics filed its DEF 14A proxy statement on April 1, 2024, detailing executive compensation and equity awards for 2022-2023.</b>

AI Summary

CAPRICOR THERAPEUTICS, INC. (CAPR) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. Capricor Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024. The filing covers the period ending May 14, 2024. The company's principal executive offices are located at 8840 Wilshire Blvd, 2nd Floor, Beverly Hills, CA 90211. The company was formerly known as Nile Therapeutics, Inc. and SMI PRODUCTS INC. The filing includes data related to equity awards and compensation for PEO and Non-PEO members for the fiscal years 2022 and 2023.

Why It Matters

For investors and stakeholders tracking CAPRICOR THERAPEUTICS, INC., this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation, including details on equity awards, which can influence investment decisions. Understanding the compensation structure and equity awards is important for shareholders to assess management's alignment with company performance and long-term strategy.

Risk Assessment

Risk Level: — CAPRICOR THERAPEUTICS, INC. shows moderate risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures without immediate financial or operational news, indicating low immediate risk.

Analyst Insight

Review the executive compensation details and equity award structures to understand potential incentives and their impact on future company performance.

Key Numbers

• 2024-04-01 — Filing Date (DEF 14A filing date)
• 2024-05-14 — Reporting Period End (Conformed period of report)
• 2023-12-31 — Fiscal Year End (Company fiscal year end)

Key Players & Entities

• CAPRICOR THERAPEUTICS, INC. (company) — Filer
• Nile Therapeutics, Inc. (company) — Former company name
• SMI PRODUCTS INC (company) — Former company name
• 8840 WILSHIRE BLVD (location) — Business and mail address

FAQ

Industry Context

Capricor Therapeutics operates in the pharmaceutical preparations industry, focusing on developing novel treatments.

Regulatory Implications

The filing is a standard DEF 14A, subject to SEC regulations for public companies regarding disclosure of executive compensation and shareholder matters.

What Investors Should Do

1. Analyze the detailed breakdown of executive compensation for PEO and Non-PEO members for fiscal years 2022 and 2023.
2. Examine the specific equity awards granted, including their fair value and adjustments, to understand incentive structures.
3. Note any changes or significant details in the proxy statement that might indicate strategic shifts or governance changes.

Key Dates

• 2024-04-01: DEF 14A Filing — Definitive Proxy Statement filed
• 2024-05-14: Reporting Period End — The period covered by the proxy statement

Year-Over-Year Comparison

This filing is a DEF 14A, which is a standard disclosure document. No prior filing data for comparison is provided in the text.

Filing Documents

• capr-20240514xdef14a.htm (DEF 14A) — 838KB
• capr-20240514xdef14a_a002.jpg (GRAPHIC) — 8KB
• capr-20240514xdef14a_a009.jpg (GRAPHIC) — 31KB
• capr-20240514xdef14a_a010.jpg (GRAPHIC) — 30KB
• capr-20240514xdef14a_bg001.jpg (GRAPHIC) — 93KB
• capr-20240514xdef14a_bg002.jpg (GRAPHIC) — 173KB
• 0001558370-24-004399.txt (&nbsp;) — 2282KB
• capr-20240514.xsd (EX-101.SCH) — 6KB
• capr-20240514_def.xml (EX-101.DEF) — 7KB
• capr-20240514_lab.xml (EX-101.LAB) — 14KB
• capr-20240514_pre.xml (EX-101.PRE) — 7KB
• capr-20240514xdef14a_htm.xml (XML) — 162KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 24 NON-EMPLOYEE DIRECTOR COMPENSATION 31 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 31 PROPOSAL 2 – RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 33 AUDIT COMMITTEE REPORT 35 PROPOSAL 3 – ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS 36 PROPOSAL 4 – AMENDMENT TO CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES 37 STOCK OWNERSHIP INFORMATION 39 OTHER INFORMATION 42 ANNEX A 43 4 Table of Contents PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF THE STOCKHOLDERS TO BE HELD ON MAY 14, 2024 COMMONLY ASKED QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING Why am I receiving these materials? We have sent you these proxy materials because the board of directors (the " Board ") of Capricor Therapeutics, Inc. (sometimes referred to as " we ", " us ", or the " Company ") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the " Annual Meeting "), including at any adjournments or postponements of the Annual Meeting. You are invited to attend the Annual Meeting in person to vote on the proposals described in this proxy statement. We intend to mail the proxy solicitation materials, combined with the Annual Report on Form 10-K for our fiscal year ended December 31, 2023, including financial statements, to stockholders on or about April 3, 2024. How do I attend the Annual Meeting? The Annual Meeting will be held on May 14, 2024, at 10:00 a.m. PDT. You may attend in person, at our principal executive offices located at 10865 Road to the Cure, Suite 150, San Diego, California 92121. Information on how to vote in person at the Annual Meeting is discussed below. Attending in Person: You will need to have a government-issued photo identification along with either your Notice and Access Card or proof of ownership of our shares of common stock as of the Record Date in order to enter the Annual Meeting. Proof of owner

View Full Filing

View this DEF 14A filing on SEC EDGAR